AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22454003 — intervention group
Group type: COMPARATOR
Intervention: Fixed extended regimen (120 days' uninterrupted active hormonal intake followed by a 4-day tablet-free interval)
Number of subjects: 1067
Study 22454003 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible(MIB) regimen
Number of subjects: 1067
Study 20430775 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lymphoscintigraphy
Number of subjects: 565
Study 20430775 — intervention group
Group type: COMPARATOR
Intervention: No preoperative lymphoscintigraphy
Number of subjects: 565
Study 18333866 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz + Combivir (lamivudine/zidovudine)
Number of subjects: 29
Study 18333866 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz + didanosine + tenofovir
Number of subjects: 29
Study 18333866 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine + lamivudine + tenofovir
Number of subjects: 29
Study 18333866 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaletra (lopinavir/ritonavir) + stavudine + lamivudine
Number of subjects: 29
Study 15672015 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (low dose ≤10 mg)
Number of subjects: 404
Study 15672015 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (high dose >10 mg)
Number of subjects: 404
Study 15672015 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 404
Study 15672015 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide and Insulin
Number of subjects: 404
Study 12024844 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic cholecystectomy (GLC)
Number of subjects: 50
Study 12024844 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 50
Study 10863393 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal instrumentation plus TTC‐HCl (test 1)
Number of subjects: 22
Study 10863393 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal instrumentation plus TTC‐HCl plus trypsin solution after extraction (test 2)
Number of subjects: 22
Study 10863393 — intervention group
Group type: COMPARATOR
Intervention: Periodontal instrumentation alone (control 1)
Number of subjects: 22
Study 10863393 — intervention group
Group type: COMPARATOR
Intervention: Periodontal instrumentation plus trypsin solution after extraction (control 2)
Number of subjects: 22
Study 7499781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 600 mg per day for 2 months
Number of subjects: 50
Study 7499781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1940092 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 101
Study 1940092 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 101
Study 1940092 — intervention group
Group type: COMPARATOR
Intervention: Waiting List control group
Number of subjects: 101
Study 1940092 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (after 4 months)
Number of subjects: 101
Study 7250177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (10 mg)
Number of subjects: 6
Study 7250177 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (10 mg)
Number of subjects: 6
Study 7250177 — intervention group
Group type: COMPARATOR
Intervention: Comparison to normal subjects
Number of subjects: 6
Study 31986315 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 33
Study 31863046 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer (GI) restorations
Number of subjects: 59
Study 31863046 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (CR) restorations
Number of subjects: 59
Study 28459163 — intervention group
Group type: COMPARATOR
Intervention: Mirror therapy
Number of subjects: 69
Study 28459163 — intervention group
Group type: COMPARATOR
Intervention: Mirror therapy + neuromuscular electrical stimulation
Number of subjects: 69
Study 26897778 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened formula (corn flour starch)
Number of subjects: 15
Study 26897778 — intervention group
Group type: COMPARATOR
Intervention: Un-thickened formula
Number of subjects: 15
Study 26897778 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 15
Study 26897778 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened formula
Number of subjects: 15
Study 23564205 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA with Daunorubicin (DNR) and AraC (AraC group)
Number of subjects: 0
Study 23564205 — intervention group
Group type: COMPARATOR
Intervention: ATRA with DNR but without AraC (no AraC group)
Number of subjects: 0
Study 21615299 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin solution (albumin-bolus group)
Number of subjects: 3141
Study 21615299 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution (saline-bolus group)
Number of subjects: 3141
Study 21615299 — intervention group
Group type: COMPARATOR
Intervention: No bolus (control group)
Number of subjects: 3141
Study 21615299 — intervention group
Group type: EXPERIMENTAL
Intervention: Any bolus (albumin or saline)
Number of subjects: 3141
Study 21615299 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-bolus group (stratum B)
Number of subjects: 3141
Study 21615299 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-bolus group (stratum B)
Number of subjects: 3141
Study 19408724 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (40 mg/ml)
Number of subjects: 12
Study 19408724 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b (15 x 10(5) U/ml)
Number of subjects: 12
Study 19408724 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (2.5 mg/ml)
Number of subjects: 12
Study 19408724 — intervention group
Group type: COMPARATOR
Intervention: Untreated keloid and hypertrophic scar, normal skin
Number of subjects: 12
Study 17218799 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg/day)
Number of subjects: 12
Study 17218799 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg/day)
Number of subjects: 12
Study 17218799 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (0 mg/day)
Number of subjects: 12
Study 17218799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine doses (0, 12, 25, 50 mg)
Number of subjects: 12
Study 15020609 — intervention group
Group type: EXPERIMENTAL
Intervention: PSC-MEC (valspodar plus mitoxantrone, etoposide, and cytarabine)
Number of subjects: 129
Study 15020609 — intervention group
Group type: COMPARATOR
Intervention: MEC (mitoxantrone, etoposide, and cytarabine)
Number of subjects: 129
Study 12047397 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 12
Study 12047397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9400485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyeloplasty
Number of subjects: 32
Study 9400485 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 32
Study 8083675 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 0
Study 8083675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2708468 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive boys in experimental conditions exposed to angry interactions
Number of subjects: 40
Study 2708468 — intervention group
Group type: EXPERIMENTAL
Intervention: High responders from the aggressive group
Number of subjects: 40
Study 2708468 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonaggressive boys)
Number of subjects: 40
Study 342318 — intervention group
Group type: COMPARATOR
Intervention: Vaccine with 6 log EID50/dose
Number of subjects: 0
Study 342318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 7 log EID50/dose
Number of subjects: 0
Study 342318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31728681 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant dextrin (10 g/day)
Number of subjects: 65
Study 31728681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 31241488 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 55
Study 31241488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 29114781 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation of once-weekly isoniazid and rifapentine
Number of subjects: 1002
Study 29114781 — intervention group
Group type: COMPARATOR
Intervention: Self-administration of once-weekly isoniazid and rifapentine
Number of subjects: 1002
Study 29114781 — intervention group
Group type: COMPARATOR
Intervention: Self-administration with reminders of once-weekly isoniazid and rifapentine
Number of subjects: 1002
Study 25457496 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (RP or RT)
Number of subjects: 2595
Study 25457496 — intervention group
Group type: COMPARATOR
Intervention: Control arm (RT with hormonal therapy, dosage ≥69Gy)
Number of subjects: 2595
Study 25457496 — intervention group
Group type: COMPARATOR
Intervention: Control arm (RT with hormonal therapy)
Number of subjects: 2595
Study 22751219 — intervention group
Group type: EXPERIMENTAL
Intervention: Milwaukee brace
Number of subjects: 10
Study 21484386 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block until postoperative day 7 (POD 7)
Number of subjects: 63
Study 21484386 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block until postoperative day 3 (POD 3)
Number of subjects: 63
Study 18565968 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAV+IRB (pravastatin 40 mg/day + irbesartan 300 mg/day)
Number of subjects: 60
Study 18565968 — intervention group
Group type: COMPARATOR
Intervention: PRAV (pravastatin 40 mg/day)
Number of subjects: 60
Study 16336332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 2340
Study 12478101 — intervention group
Group type: EXPERIMENTAL
Intervention: HM3
Number of subjects: 167
Study 12478101 — intervention group
Group type: COMPARATOR
Intervention: Lithostar Plus
Number of subjects: 167
Study 10730982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (1.9 mg/d) continuous infusion from Days 14 to 26 after estrus
Number of subjects: 12
Study 10730982 — intervention group
Group type: COMPARATOR
Intervention: Saline control (Group 1)
Number of subjects: 12
Study 10730982 — intervention group
Group type: COMPARATOR
Intervention: Saline pregnant (Group 3)
Number of subjects: 12
Study 10730982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (Group 2)
Number of subjects: 12
Study 8774294 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose hMG (150 IU twice daily)
Number of subjects: 171
Study 8774294 — intervention group
Group type: COMPARATOR
Intervention: Single-dose hMG (300 IU once daily)
Number of subjects: 171
Study 8774294 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose hMG
Number of subjects: 171
Study 8774294 — intervention group
Group type: COMPARATOR
Intervention: Single-dose hMG
Number of subjects: 171
Study 1590574 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered at 15 mg/kg body weight per hour for 10 min after induction, then reduced to 6 mg/kg body weight per hour
Number of subjects: 60
Study 1590574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg before induction with propofol at similar dosage to group I
Number of subjects: 60
Study 1590574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg before induction with propofol at an infusion rate of 6 mg/kg body weight from the beginning
Number of subjects: 60
Study 6204377 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological saline
Number of subjects: 0
Study 6204377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextranomer beads
Number of subjects: 0
Study 6204377 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine skin
Number of subjects: 0
Study 6204377 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium foil
Number of subjects: 0
Study 6204377 — intervention group
Group type: EXPERIMENTAL
Intervention: Double layer bandage
Number of subjects: 0
Study 6204377 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 0
Study 30146931 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 15480
Study 30146931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15480
Study 26453188 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview (BNI), a 10-15 minute structured interview
Number of subjects: 167
Study 26453188 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MOTIV), a 30-45 minute intervention
Number of subjects: 167
Study 26453188 — intervention group
Group type: COMPARATOR
Intervention: Control group (received only a list of substance use treatment resources)
Number of subjects: 167
Study 24958910 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 bivalent vaccine
Number of subjects: 5404
Study 24958910 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated women)
Number of subjects: 5404
Study 23076429 — intervention group
Group type: EXPERIMENTAL
Intervention: Target fixation (eyes free, pointer guided by foveal vision)
Number of subjects: 0
Study 23076429 — intervention group
Group type: EXPERIMENTAL
Intervention: Central fixation (eyes fixed straight ahead, pointer guided by peripheral vision)
Number of subjects: 0
Study 23076429 — intervention group
Group type: EXPERIMENTAL
Intervention: Remembered auditory, visual, and bimodal targets
Number of subjects: 0
Study 23076429 — intervention group
Group type: COMPARATOR
Intervention: Comparison with young adults
Number of subjects: 0
Study 19628211 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of at least one epsilon4 allele (epsilon4+)
Number of subjects: 1255
Study 19628211 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of epsilon4+ to multivariate ROC model
Number of subjects: 1255
Study 18561117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 200 microg once daily
Number of subjects: 502
Study 18561117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 17012860 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib vaccine
Number of subjects: 913
Study 17012860 — intervention group
Group type: COMPARATOR
Intervention: Tritanrix HepB/Hiberix (control)
Number of subjects: 913
Study 12740676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower molecular weight hyaluronic acid plus physical therapy
Number of subjects: 37
Study 12740676 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher molecular weight hyaluronic acid plus physical therapy
Number of subjects: 37
Study 12740676 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 37
Study 11763934 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxed floss
Number of subjects: 24
Study 11763934 — intervention group
Group type: EXPERIMENTAL
Intervention: Woven floss
Number of subjects: 24
Study 11763934 — intervention group
Group type: EXPERIMENTAL
Intervention: Shred-resistant floss
Number of subjects: 24
Study 11763934 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwaxed floss
Number of subjects: 24
Study 9286743 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (1 mg.kg‐1.day‐1) for 28 days
Number of subjects: 18
Study 9286743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8336223 — intervention group
Group type: EXPERIMENTAL
Intervention: Therabite System combined with unassisted exercise
Number of subjects: 3
Study 8336223 — intervention group
Group type: COMPARATOR
Intervention: Unassisted exercise
Number of subjects: 3
Study 8336223 — intervention group
Group type: COMPARATOR
Intervention: Mechanically assisted mandibular mobilization with stacked tongue depressors combined with unassisted exercise
Number of subjects: 3
Study 3948042 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg intramuscular ketamine (Group I)
Number of subjects: 34
Study 3948042 — intervention group
Group type: COMPARATOR
Intervention: 10 mg epidural ketamine (Group II)
Number of subjects: 34
Study 3948042 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg epidural ketamine (Group III)
Number of subjects: 34
Study 29462225 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution, once-daily for 48 weeks
Number of subjects: 1655
Study 29462225 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1655
Study 25834964 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate and fentanyl (0.25 mg/kg etomidate, 1.30 μg/kg fentanyl)
Number of subjects: 44
Study 25834964 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (1.25 mg/kg)
Number of subjects: 44
Study 24329543 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 960
Study 24329543 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 960
Study 24329543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 960
Study 21594719 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Program (WA)
Number of subjects: 90
Study 21594719 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-Strengthening Exercises (MS)
Number of subjects: 90
Study 21594719 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 90
Study 19744230 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 63
Study 19744230 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 63
Study 19744230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 18627363 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg zidovudine and 150 mg lamivudine B.I.D. for 6 months
Number of subjects: 59
Study 18627363 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 59
Study 16129365 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative megatherapy (melphalan, etoposide, and carboplatin) with autologous stem-cell transplantation (n=149)
Number of subjects: 295
Study 16129365 — intervention group
Group type: COMPARATOR
Intervention: Oral maintenance chemotherapy with cyclophosphamide (n=146)
Number of subjects: 295
Study 16129365 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative megatherapy
Number of subjects: 295
Study 16129365 — intervention group
Group type: COMPARATOR
Intervention: Oral maintenance chemotherapy
Number of subjects: 295
Study 12820929 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt group
Number of subjects: 8
Study 12820929 — intervention group
Group type: COMPARATOR
Intervention: Non‐iodized salt group
Number of subjects: 8
Study 12820929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8
Study 10791213 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 treatment (PG group; n = 19)
Number of subjects: 43
Study 10791213 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 43
Study 8778905 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone (30 mg PO)
Number of subjects: 75
Study 8778905 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 1739177 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic cholangiography and stone removal prior to open cholecystectomy
Number of subjects: 34
Study 1739177 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy, operative cholangiography, and common duct exploration
Number of subjects: 34
Study 6143664 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Metoprolol (beta‐1‐selective blockade)
Number of subjects: 10
Study 6143664 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Bupranolol (non‐selective beta‐blockade)
Number of subjects: 10
Study 6143664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 31405919 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachyspira aalborgi and Brachyspira pilosicoli isolates cultured and sequenced from individuals with colonic spirochaetosis.
Number of subjects: 745
Study 31405919 — intervention group
Group type: COMPARATOR
Intervention: Standard 16S amplicon sequencing using primers for human microbiota studies.
Number of subjects: 745
Study 28942587 — intervention group
Group type: EXPERIMENTAL
Intervention: benzydamine HCl
Number of subjects: 60
Study 28942587 — intervention group
Group type: COMPARATOR
Intervention: sodium bicarbonate
Number of subjects: 60
Study 26011816 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide/Voglibose (fixed-dose combination of mitiglinide 10 mg and voglibose 0.2 mg)
Number of subjects: 30
Study 26011816 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (0.5 mg)
Number of subjects: 30
Study 24408751 — intervention group
Group type: EXPERIMENTAL
Intervention: High well-being participants (10% of participants)
Number of subjects: 128
Study 24408751 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect balance
Number of subjects: 128
Study 22260834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM)
Number of subjects: 320
Study 22260834 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir (ADV)
Number of subjects: 320
Study 22260834 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 320
Study 20527504 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Pharma (CTP)
Number of subjects: 15
Study 20527504 — intervention group
Group type: COMPARATOR
Intervention: Colgate Regular Toothpaste (CRT)
Number of subjects: 15
Study 17672383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1.0 and 2.0 mg/70 kg, orally administered)
Number of subjects: 20
Study 17672383 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.25 and 0.50 mg/70 kg, subcutaneously administered)
Number of subjects: 20
Study 17672383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17672383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 20
Study 15689196 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-interactive pressure algesimetry
Number of subjects: 0
Study 12660838 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 0